World Reacts to Bextra Ban
While the United States Food and Drug Administration was the first to ask Pfizer to halt sales of their pain medication Bextra on April 7, 2005, the rest of the world is reacting in suit.
The Hong Kong Health Department issued a release the same day urging Bextra users to “stop taking Bextra and contact their physicians about appropriate treatment options," prompting the drug’s importer Pfizer Corporation Hong Kong Ltd. to immediately stop distributing and selling the drug.
Canadian health officials also asked Pfizer to halt sales of the medication, basing its decision on “an ongoing review of information with regard to serious, potentially life-threatening skin reactions." Canadian officials have requested Pfizer "to submit evidence to establish the safety of this drug product under the conditions of use for which it is recommended."
Hours after the FDA’s request, the European Union took a similar approach, asking Pfizer to suspend sales of Bextra in all 25 EU member nations. Pfizer complied with this request as well.
Singapore joined the widespread ban on April 8, when the Health Sciences Authority asked Pfizer to withdraw Bextra from the Singapore market.
Weitz & Luxenberg is no longer accepting Bextra cases.
see also:
FDA Press Release
Bextra - FDA Press Release: Bextra Recall, Celebrex Black Box WarningBextra lawyer-The FDA Bextra Recall and the Celebrex Black Box Warning
Public Citizen Petition
Bextra Lawyer - Public Citizen Bextra Recall PetitionBextra Lawyer - Bextra recall petition from Public Citizen to the FDA.
About the Bextra Recall
Bextra lawyers - about the FDA Bextra recallBextra Withdrawal: Letter to clients about the FDA Bextra recall
